{
    "nct_id": "NCT03367156",
    "official_title": "A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients",
    "inclusion_criteria": "* Diagnosis of cancer.\n* Dyspnea with an average intensity >= 4 on the dyspnea NRS (range 0-10) over the past week.\n* Radiologic suspicion of thoracic involvement, such as primary or metastatic lung cancer, lymphangitic carcinomatosis, airway infiltration, lymphadenopathy, pleural or chest wall invasion.\n* Seen at an outpatient clinic at MD Anderson Cancer Center or Lyndon B. Johnson (LBJ) Hospital General Oncology Clinic.\n* Able to communicate in English or Spanish.\n* Karnofsky performance status >= 30%.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Delirium (i.e., score > 13 on the Memorial Delirium Assessment Scale; range 1-30).\n* Oxygen saturation < 90% despite supplemental oxygen > 6 L/minute.\n* Previous allergic reactions to dexamethasone.\n* Diagnosis of diabetes mellitus uncontrolled with oral hypoglycemic agents or insulin.\n* Postsurgical open wound that has not healed at the time of enrollment.\n* Any infection requiring antibiotics at the time of study enrollment.\n* Major surgery within the past 2 weeks.\n* Megestrol use at the time of study enrollment.\n* Neutropenia (absolute neutrophil count < 1.0 x 10^9/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).\n* Currently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist.\n* Severe anemia (hemoglobin < 8 g/L) not corrected prior to study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).\n* Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment.\n* Heart failure exacerbation at the time of study enrollment.\n* Expected to undergo therapeutic thoracentesis in the next 2 weeks.\n* High anxiety score (>= 15/21) on the Hospital Anxiety and Depression Scale (HADS).\n* Chronic systemic corticosteroid use (> 14 days) at the time of study enrollment.\n* Any expected corticosteroid use during study enrollment at higher doses than will be used in this study.",
    "miscellaneous_criteria": ""
}